BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 28027895)

  • 1. Low Level of Blood CD4
    Judd J; Dulaimi E; Li T; Millenson MM; Borghaei H; Smith MR; Al-Saleem T
    Clin Lymphoma Myeloma Leuk; 2017 Feb; 17(2):83-88. PubMed ID: 28027895
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Clinical Significance of Detecting CD4
    Liu W; Zhagn GX; Shi WZ; Dong L; Liu H; Shen XL
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Apr; 25(2):449-454. PubMed ID: 28446291
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CD4(+) tumor infiltrating lymphocytes are prognostic and independent of R-IPI in patients with DLBCL receiving R-CHOP chemo-immunotherapy.
    Keane C; Gill D; Vari F; Cross D; Griffiths L; Gandhi M
    Am J Hematol; 2013 Apr; 88(4):273-6. PubMed ID: 23460351
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Circulating Low Absolute CD4+ T Cell Counts May Predict Poor Prognosis in Extranodal NK/T-Cell Lymphoma Patients Treating with Pegaspargase-Based Chemotherapy.
    Zhang YP; Zhang R; Zhu HY; Wang L; Wu YJ; Liang JH; Shi WY; Liu H; Xu W; Li JY
    Cancer Res Treat; 2019 Jan; 51(1):368-377. PubMed ID: 29764116
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low absolute CD4
    Zeng R; Zhu W; Jiang L; Zhu X; Gao Y; Xia Y; Bai B; Shikama N; Janetos TM; Dalia S; Alpdogan O; Wang X; Zhu L; Li P
    Ann Transl Med; 2022 Oct; 10(20):1119. PubMed ID: 36388826
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low absolute CD4
    He L; Liang JH; Wu JZ; Li Y; Qin SC; Miao Y; Wu YJ; Wang Y; Wang L; Fan L; Li JY; Xu W
    Tumour Biol; 2016 Sep; 37(9):12589-12595. PubMed ID: 27388165
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Analysis of survival and prognosis in 409 newly diagnosed patients with diffuse large B-cell lymphoma].
    Wen J; Zhou J; Liu Z; Liu T; Xu C
    Zhonghua Xue Ye Xue Za Zhi; 2014 Apr; 35(4):318-24. PubMed ID: 24759020
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic Value of Anemia and C-Reactive Protein Levels in Diffuse Large B-Cell Lymphoma.
    Adams HJ; de Klerk JM; Fijnheer R; Heggelman BG; Dubois SV; Nievelstein RA; Kwee TC
    Clin Lymphoma Myeloma Leuk; 2015 Nov; 15(11):671-9. PubMed ID: 26361646
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Absolute lymphocyte count at the time of first relapse predicts survival in patients with diffuse large B-cell lymphoma.
    Porrata LF; Ristow K; Habermann TM; Witzig TE; Inwards DJ; Markovic SN
    Am J Hematol; 2009 Feb; 84(2):93-7. PubMed ID: 19123458
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Enhanced International Prognostic Index for Diffuse Large B-cell Lymphoma.
    Yang Y; Wang L; Ma Y; Han T; Huang M
    Am J Med Sci; 2017 May; 353(5):459-465. PubMed ID: 28502332
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic superiority of the National Comprehensive Cancer Network International Prognostic Index over pretreatment whole-body volumetric-metabolic FDG-PET/CT metrics in diffuse large B-cell lymphoma.
    Adams HJ; de Klerk JM; Fijnheer R; Heggelman BG; Dubois SV; Nievelstein RA; Kwee TC
    Eur J Haematol; 2015 Jun; 94(6):532-9. PubMed ID: 25311082
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum albumin level at diagnosis of diffuse large B-cell lymphoma: an important simple prognostic factor.
    Bairey O; Shacham-Abulafia A; Shpilberg O; Gurion R
    Hematol Oncol; 2016 Dec; 34(4):184-192. PubMed ID: 26052918
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low absolute lymphocyte count is a poor prognostic factor in diffuse-large-B-cell-lymphoma.
    Cox MC; Nofroni I; Ruco L; Amodeo R; Ferrari A; La Verde G; Cardelli P; Montefusco E; Conte E; Monarca B; Aloe-Spiriti MA
    Leuk Lymphoma; 2008 Sep; 49(9):1745-51. PubMed ID: 18798109
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NCCN-IPI score-independent prognostic potential of pretreatment uric acid levels for clinical outcome of diffuse large B-cell lymphoma patients.
    Prochazka KT; Melchardt T; Posch F; Schlick K; Deutsch A; Beham-Schmid C; Weiss L; Gary T; Neureiter D; Klieser E; Greil R; Neumeister P; Egle A; Pichler M
    Br J Cancer; 2016 Nov; 115(10):1264-1272. PubMed ID: 27764838
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Peripheral blood absolute lymphocyte/monocyte ratio as a useful prognostic factor in diffuse large B-cell lymphoma in the rituximab era.
    Watanabe R; Tomita N; Itabashi M; Ishibashi D; Yamamoto E; Koyama S; Miyashita K; Takahashi H; Nakajima Y; Hattori Y; Motohashi K; Takasaki H; Ohshima R; Hashimoto C; Yamazaki E; Fujimaki K; Sakai R; Fujisawa S; Motomura S; Ishigatsubo Y
    Eur J Haematol; 2014 Mar; 92(3):204-10. PubMed ID: 24283206
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Negative prognostic impact of low absolute CD4
    Zhang XY; Xu J; Zhu HY; Wang Y; Wang L; Fan L; Wu YJ; Li JY; Xu W
    Cancer Sci; 2016 Oct; 107(10):1471-1476. PubMed ID: 27465799
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Implications of infiltrating immune cells within bone marrow of patients with diffuse large B-cell lymphoma.
    Jeong J; Oh EJ; Yang WI; Kim SJ; Yoon SO
    Hum Pathol; 2017 Jun; 64():222-231. PubMed ID: 28438619
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The significance of pretreatment anemia in the era of R-IPI and NCCN-IPI prognostic risk assessment tools: a dual-center study in diffuse large B-cell lymphoma patients.
    Troppan KT; Melchardt T; Deutsch A; Schlick K; Stojakovic T; Bullock MD; Reitz D; Beham-Schmid C; Weiss L; Neureiter D; Wenzl K; Greil R; Neumeister P; Egle A; Pichler M
    Eur J Haematol; 2015 Dec; 95(6):538-44. PubMed ID: 25677782
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cd4+ T-cell immune response to large B-cell non-Hodgkin's lymphoma predicts patient outcome.
    Ansell SM; Stenson M; Habermann TM; Jelinek DF; Witzig TE
    J Clin Oncol; 2001 Feb; 19(3):720-6. PubMed ID: 11157023
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical Impact of the Cell-of-Origin Classification and the MYC/ BCL2 Dual Expresser Status in Diffuse Large B-Cell Lymphoma Treated Within Prospective Clinical Trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group.
    Staiger AM; Ziepert M; Horn H; Scott DW; Barth TFE; Bernd HW; Feller AC; Klapper W; Szczepanowski M; Hummel M; Stein H; Lenze D; Hansmann ML; Hartmann S; Möller P; Cogliatti S; Lenz G; Trümper L; Löffler M; Schmitz N; Pfreundschuh M; Rosenwald A; Ott G;
    J Clin Oncol; 2017 Aug; 35(22):2515-2526. PubMed ID: 28525305
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.